Gefitinib - CAS 184475-35-2

Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.

Apoptosis, EGFR, Autophagy, Tyrosine Kinases

JAK/STAT signaling, Angiogenesis, Autophagy, Tyrosine Kinase/Adaptors, Apoptosis

184438

>99.99%

C22H24ClFN4O3

446.9

N(C=1C2=C(C=C(OC)C(OCCCN3CCOCC3)=C2)N=CN1)C4=CC(Cl)=C(F)C=C4

-20°C

Ice Packs

Small Compound